Literature DB >> 1327786

Evidence of an in vitro association between human immunodeficiency virus antigen P24 and Epstein-Barr virus DNA.

P Lardelli1, S M Steinberg, C Campelo, A F de Aranguiz, L Sarría, M T Gorriño, R Cisterna.   

Abstract

To investigate the association between human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV), simultaneous determinations of HIV antigen (HIV Ag) p24 and EBV DNA were performed in lymphocyte culture supernatants from 63 individuals at risk of HIV infection. In vitro data, together with HIV immune status results, were subjected to a statistical analysis. HIV infection was identified in 49 patients (78%); of these, in vitro EBV DNA was found in 44 individuals (90%), while in only 3 of the 14 non-infected ones (21%). Statistical analysis demonstrated a close relationship between evidence of HIV infection and in vitro detection of EBV DNA (87.3% concordant with 95% confidence interval: 76.5%-94.5%). Furthermore, a strong dependence was revealed between the presence of EBV DNA and HIV Ag in culture (p less than 0.00001). These results indicate the existence of in vitro viral interactions, with likely in vivo implications in the pathogenesis and evolution of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327786     DOI: 10.1007/bf01967068

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

Review 1.  Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus.

Authors:  A F List; F A Greco; L B Vogler
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

2.  HIV revealed: toward a natural history of the infection.

Authors:  D Baltimore; M B Feinberg
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

3.  Silent HIV infections.

Authors:  W A Haseltine
Journal:  N Engl J Med       Date:  1989-06-01       Impact factor: 91.245

4.  Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods.

Authors:  D T Imagawa; M H Lee; S M Wolinsky; K Sano; F Morales; S Kwok; J J Sninsky; P G Nishanian; J Giorgi; J L Fahey
Journal:  N Engl J Med       Date:  1989-06-01       Impact factor: 91.245

5.  Isolation of lymphadenopathy-associated virus (LAV) and detection of LAV antibodies from US patients with AIDS.

Authors:  F Barré-Sinoussi; U Mathur-Wagh; F Rey; F Brun-Vezinet; S R Yancovitz; C Rouzioux; L Montagnier; D Mildvan; J C Chermann
Journal:  JAMA       Date:  1985 Mar 22-29       Impact factor: 56.272

6.  Enhanced antibody responses to Epstein-Barr virus in HIV-infected homosexual men.

Authors:  M A Rahman; L A Kingsley; M K Breinig; M Ho; J A Armstrong; R W Atchison; D W Lyter; C R Rinaldo
Journal:  J Infect Dis       Date:  1989-03       Impact factor: 5.226

7.  Active replication of human immunodeficiency virus type 1 by peripheral blood mononuclear cells following coincubation with herpes viruses.

Authors:  M Tremblay; M Gornitsky; M A Wainberg
Journal:  J Med Virol       Date:  1989-10       Impact factor: 2.327

Review 8.  Possible viral interactions in the acquired immunodeficiency syndrome (AIDS).

Authors:  M S Hirsch; R T Schooley; D D Ho; J C Kaplan
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct

9.  Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus.

Authors:  P R Skolnik; B R Kosloff; M S Hirsch
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

10.  An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat.

Authors:  S Kenney; J Kamine; D Markovitz; R Fenrick; J Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

View more
  1 in total

1.  Association between HIV and other DNA viruses in vitro.

Authors:  R Cisterna; C Campelo; T Gorriño; C Malavé; L Sarría; P Lardelli; A Fernandez de Aranguiz; L Madariaga
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.